Cargando…
ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia
This study aimed to estimate the absorption, distribution, metabolism and excretion (ADME) properties and safety of LDT5, a lead compound for oral treatment of benign prostatic hyperplasia that has previously been characterized as a multi-target antagonist of α(1A)-, α(1D)-adrenoceptors and 5-HT(1A)...
Autores principales: | Noël, F., Nascimento-Viana, J.B., Romeiro, L.A.S., Silva, R.O., Lemes, L.F.N., Oliveira, A.S., Giorno, T.B.S., Fernandes, P.D., Silva, C.L.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5188857/ https://www.ncbi.nlm.nih.gov/pubmed/27901175 http://dx.doi.org/10.1590/1414-431X20165542 |
Ejemplares similares
-
Zinc is an inhibitor of the LdtR transcriptional activator
por: Pagliai, Fernando A., et al.
Publicado: (2018) -
High-impact exercise in rats prior to and during suspension can prevent
bone loss
por: Yanagihara, G.R., et al.
Publicado: (2016) -
Hormonal therapy with estradiol and drospirenone improves
endothelium-dependent vasodilation in the coronary bed of ovariectomized
spontaneously hypertensive rats
por: Borgo, M.V., et al.
Publicado: (2015) -
Intensity of swimming exercise influences aortic reactivity in
rats
por: Brito, A.F., et al.
Publicado: (2015) -
3104 Characterizing the top 100 articles in benign prostatic hyperplasia literature using bibliometric analysis
por: Cruz, Alan Paniagua, et al.
Publicado: (2019)